Zhejiang Taimei Medical Technology Co., Ltd. reported its unaudited consolidated interim results for the six months ended June 30, 2025. The company experienced a decline in revenue, which impacted their financial performance. Despite this, the gross profit margin slightly increased from 40.7% in 2024 to 41.0% in 2025. The company recorded a net loss of RMB29.3 million for the first half of 2025, an improvement from a loss of RMB175.3 million in the same period the previous year. After adjusting for listing expenses and share-based payments, the adjusted net loss was RMB28.7 million, marking a 41.7% year-on-year decrease. Research and development expenses decreased by 26.0% to RMB37.7 million, primarily due to reduced staff costs. Selling expenses also decreased by 26.6% to RMB37.6 million, while administrative expenses saw a significant reduction of 73.4% to RMB57.7 million, largely due to decreased share-based payments related to previous acquisitions. The company reported net impairment losses on financial and contract assets of RMB5.5 million, up from RMB1.3 million in the previous year, driven by increased credit risk from a few customers. The company continues to provide solutions for the pharmaceutical and medical device industry, offering cloud-based software and digital services.